Financial Data and Key Metrics Changes - Total revenue for Q1 2025 grew by 0.3% year over year to $61.3 million [5][32] - Lymphedema business line revenue decreased by 3% year over year to $50.6 million, while airway clearance revenue increased by 22% to $10.7 million [5][32] - Gross margins increased by 290 basis points year over year, while adjusted EBITDA decreased by 125% year over year [5][32] Business Line Data and Key Metrics Changes - Lymphedema product sales decreased by $1.8 million or 3% to $50.6 million, while airway clearance product sales increased by $1.9 million or 22% to $10.7 million [32] - Sales headcount in the lymphedema business decreased from 280 to 264, but is expected to increase to over 300 by the end of 2025 [10][25] Market Data and Key Metrics Changes - The company is maintaining a strong number two position in the airway clearance market, with significant growth in the bronchiectasis market [16][84] - The company expects revenue in the second quarter to be in the range of $73 million to $76 million, with full-year revenue guidance revised to $309 million to $315 million [14][34] Company Strategy and Development Direction - The company is focused on three strategic priorities: improving access to care, expanding treatment options, and enhancing lifetime patient value [17][26] - Investments in technology and human capital are aimed at streamlining sales and order management processes, including the launch of a new Salesforce CRM module [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential despite short-term challenges related to sales vacancies and CRM implementation [13][38] - The company anticipates a return to growth in the lymphedema channel as sales optimization strategies take effect [25][70] Other Important Information - The company ended the quarter with $83.6 million in cash, reflecting a decrease due to stock buybacks and annual bonus payments [6][34] - The company is actively monitoring global trade policies and assessing potential tariff impacts on cost of goods sold, expecting a total impact of less than $5 million in 2025 [35][36] Q&A Session Summary Question: Revenue guidance assumptions for the year - Management discussed the importance of hiring speed and sales rep proficiency with the new CRM tool as key drivers for revenue guidance [42][44] Question: Growth expectations for 2026 - Management indicated that while they are not ready to comment on 2026, they expect to exit 2025 with more momentum than in the first half of the year [50][52] Question: Updates on Nimble product launch - Management reported strong adoption of Nimble, with no manufacturing challenges and positive feedback from the market [61][62] Question: Airway clearance business growth sustainability - Management attributed growth in the airway clearance business to strategic partnerships and product placement agreements with DMEs [81][84] Question: Rep productivity and CRM tool impact - Management explained that the new CRM tool is designed to enhance productivity and efficiency for sales reps, which is expected to improve overall performance [92][93]